Acadian Asset Management’s Mereo BioPharma MREO Stock Holding History

Acadian Asset Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-209,084	Closed	-$68K	–	2141
2026 Q1	$68K	Buy	209,084 +147,649	+240%	+$63.4K	﹤0.01%	1814
2025 Q4	$24K	Sell	61,435 -194,943	-76%	-$371K	﹤0.01%	1896
2025 Q3	$522K	Buy	+256,378	New	+$473K	﹤0.01%	1203
2024 Q1	–	Sell	-62,843	Closed	-$144K	–	1706
2023 Q4	$144K	Buy	+62,843	New	+$120K	﹤0.01%	1293
2023 Q2	–	Sell	-191,899	Closed	-$134K	–	1843
2023 Q1	$134K	Buy	+191,899	New	+$173K	﹤0.01%	1337
2019 Q3	–	Sell	-1,302	Closed	-$3K	–	1960
2019 Q2	$3K	Buy	+1,302	New	+$5.69K	﹤0.01%	1704

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management's MREO Position: Q2 2026 in Review

Acadian Asset Management sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 209,084 shares — an estimated $68K sold.

Acadian Asset Management first reported a position in MREO in Q2 2019 and held it in 6 quarters. The position peaked at $522K in Q3 2025. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Acadian Asset Management reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
Acadian Asset Management sold 209,084 Mereo BioPharma shares in Q2 2026, an estimated $68K.
Acadian Asset Management first reported a position in Mereo BioPharma in Q2 2019 and held it in 6 quarters.
Acadian Asset Management's Mereo BioPharma position peaked at $522K in Q3 2025.
60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.